April 19, 2018 / 9:33 AM / 3 months ago

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

April 19 (Reuters) - Adamas Pharmaceuticals Inc:

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

* SAYS PATIENTS RECEIVING GOCOVRI EXPERIENCED LONG-TERM DURABILITY FOR UP TO TWO YEARS

* SAYS SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY-PUBLISHED CONTROLLED PHASE 3 STUDIES

* SAYS RESULTS DEMONSTRATED THAT GOCOVRI WAS GENERALLY WELL TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below